Cargando…

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation

INTRODUCTION: Long wait times for kidney transplants have prompted investigation into strategies to decrease the discarding of potentially viable organs. Recent reports suggest that kidneys from hepatitis C virus (HCV)−infected donors may be transplanted into HCV-naive donors followed by direct-acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sise, Meghan E., Strohbehn, Ian A., Chute, Donald F., Gustafson, Jenna, Van Deerlin, Vivianna M., Smith, Jennifer R., Gentile, Caren, Wojciechowski, David, Williams, Winfred W., Elias, Nahel, Chung, Raymond T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136432/ https://www.ncbi.nlm.nih.gov/pubmed/32280841 http://dx.doi.org/10.1016/j.ekir.2020.01.001

Ejemplares similares

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
por: Chen, Jin, et al.
Publicado: (2020)

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov, Konstantin, et al.
Publicado: (2020)

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
por: Eisenberger, Ute, et al.
Publicado: (2018)

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
por: Bell, Allison M., et al.
Publicado: (2016)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018)

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019)

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
por: Weiss, Lina, et al.
Publicado: (2018)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
por: Ng, Xinyi, et al.
Publicado: (2018)

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients
por: Axelrod, David A., et al.
Publicado: (2020)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients
por: Reese, Peter P., et al.
Publicado: (2023)

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
por: Liu, Chen-Hua, et al.
Publicado: (2020)

Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
por: Pijnenburg, Daniëlle W M, et al.
Publicado: (2020)

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
por: Hézode, Christophe, et al.
Publicado: (2019)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
por: Lee, Youn Jae, et al.
Publicado: (2019)

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
por: Puenpatom, Amy, et al.
Publicado: (2020)

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
por: Yao, Yinan, et al.
Publicado: (2017)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
por: Sulejmani, Nimisha, et al.
Publicado: (2018)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
por: Li, Haiyan, et al.
Publicado: (2020)

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
por: George, Jacob, et al.
Publicado: (2018)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016)

Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial
por: Wei, Lai, et al.
Publicado: (2020)

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
por: Jang, Eun Sun, et al.
Publicado: (2021)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Safety and efficacy of elbasvir/grazoprevir in patients infected with hepatitis C virus genotype 4 in Qassim region of Saudi Arabia
por: Murgod, Shivananda E., et al.
Publicado: (2023)

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study
por: Jacobson, Ira M., et al.
Publicado: (2019)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
por: Flamm, Steven, et al.
Publicado: (2019)

Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
por: Gonzalez-Peralta, Regino P., et al.
Publicado: (2023)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
por: Reau, Nancy, et al.
Publicado: (2017)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France
por: Maunoury, Franck, et al.
Publicado: (2018)

Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2019)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
por: Lin, Yi-Chun, et al.
Publicado: (2019)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
por: Hung, Hsuan-Yu, et al.
Publicado: (2021)

Perioperative Comparison of Preemptive and Non-Preemptive Renal Transplant Recipients
por: Aytekin, Sami, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n3ejhcgms8ckqcp73sir3aat5c